Drugs / gpASIT+™
gpASIT+™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03724240 | Jan → Sep 2019 | seasonal allergic rhinitis | ASIT Biotech S.A. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gpASIT+ | “gpASIT+™ (Grass Pollen-ASIT+™)” NCT03724240 ↗ |
| Known as | gpASIT+TM | “Biological: gpASIT+TM” NCT03724240 ↗ |
| Known as | Grass Pollen-ASIT+ | “gpASIT+™ (Grass Pollen-ASIT+™)” NCT03724240 ↗ |
| Modality | Peptide | “with a grass pollen peptide concentration of 100 µg/mL.” NCT03724240 ↗ |
| Route | Subcutaneous | “The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.” NCT03724240 ↗ |